Product Pipeline
Berna Biotech has administered RC-529 to patients as a vaccine adjuvant in Phase III clinical trials in Argentina as part of their two-dose Hepatitis B vaccine. Preliminary results indicate that patients achieved more than 95% seroprotection after two injections within one month. We are involved in multiple partnership discussions pertaining to this novel vaccine adjuvant.

Related News
04/08/2002 Rhein Biotech and Corixa enter into license and supply agreement
01/08/2002 Corixa reports positive results for its Phase III trial of RC-529 synthetic adjuvant
10/29/2001 Corixa and Wyeth Lederle Vaccines amend agreement
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.